NasdaqCM - Delayed Quote • USD
Champions Oncology, Inc. (CSBR)
At close: April 19 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Apr 2024) | Next Qtr. (Jul 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -0.16 | -0.1 | -0.63 | -0.34 |
| Low Estimate | -0.16 | -0.1 | -0.63 | -0.34 |
| High Estimate | -0.16 | -0.1 | -0.63 | -0.34 |
| Year Ago EPS | -0.19 | -0.16 | -0.39 | -0.63 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Apr 2024) | Next Qtr. (Jul 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | 12.69M | 13.1M | 48.84M | 53.67M |
| Low Estimate | 12.69M | 13.1M | 48.84M | 53.67M |
| High Estimate | 12.69M | 13.1M | 48.84M | 53.67M |
| Year Ago Sales | 13.07M | 13.06M | 53.87M | 48.84M |
| Sales Growth (year/est) | -2.90% | 0.30% | -9.30% | 9.90% |
Earnings History
| CURRENCY IN USD | 4/30/2023 | 7/31/2023 | 10/31/2023 | 1/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.12 | -0.11 | -0.17 | -0.06 |
| EPS Actual | -0.19 | -0.16 | -0.15 | -0.16 |
| Difference | -0.07 | -0.05 | 0.02 | -0.1 |
| Surprise % | -58.30% | -45.50% | 11.80% | -166.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Apr 2024) | Next Qtr. (Jul 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.16 | -0.1 | -0.63 | -0.34 |
| 7 Days Ago | -0.16 | -0.1 | -0.63 | -0.34 |
| 30 Days Ago | -0.16 | -0.1 | -0.63 | -0.34 |
| 60 Days Ago | -0.08 | 0 | -0.59 | 0.05 |
| 90 Days Ago | -0.08 | 0 | -0.59 | 0.05 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Apr 2024) | Next Qtr. (Jul 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CSBR | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 15.80% | -- | -- | 1.60% |
| Next Qtr. | 37.50% | -- | -- | 10.50% |
| Current Year | -61.50% | -- | -- | 5.20% |
| Next Year | 46.00% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 15.00% | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Downgrade | Craig-Hallum: Buy to Hold | 3/13/2024 |
| Maintains | Roth MKM: Buy to Buy | 9/22/2023 |
| Maintains | Roth Capital: Buy | 3/15/2021 |
| Initiated | Benchmark: Speculative Buy | 11/18/2019 |
| Initiated | Roth Capital: Buy | 9/20/2019 |
| Downgrade | Janney Montgomery Scott: Buy to Neutral | 7/24/2019 |
Related Tickers
PKBO Peak Bio, Inc.
0.0052
0.00%
ICCC ImmuCell Corporation
5.02
-0.20%
IPHA Innate Pharma S.A.
2.4400
+1.67%
DYAI Dyadic International, Inc.
1.5900
0.00%
AKTX Akari Therapeutics, Plc
1.1662
-0.32%
LSTA Lisata Therapeutics, Inc.
2.7000
+1.12%
GNTA Genenta Science S.p.A.
3.9010
-0.74%
ANEB Anebulo Pharmaceuticals, Inc.
2.7800
+1.09%
ESLA Estrella Immunopharma, Inc.
1.0700
+4.90%
VALN Valneva SE
7.58
-3.15%